

SEQUENT SCIENTIFIC LTD

DATE- 22 JULY 2024



About Company

Sequent Scientific is India's leading animal health company, with presence in 5+ continents across 100 countries. Sequent Scientific Limited provides a wide-ranging portfolio of animal health products, including Finished Dose Formulations, APIs, as well as analytical services to the pharmaceutical and life sciences industries. The company has 2 business segments: Formulation and API. As of FY23, API business now has 29 USVMFs + 18 CEPs (registered 5 VMFs & 3 CEPs in FY23). It has also signed a long-term master supply arrangement with a global Top-10 animal health company. API has 30+ commercial API with 3 manufacturing facilities and 1 R&D center. Its Mahad site received certifications for EHS from TÜV NORD CERT GmbH. ~70% of its sales are in regulated market. The company has 1000+ finished dosage formulations, with 6 manufacturing facilities in Europe, Turkey, Brazil and India and 5 R&D centers dedicated to the formulation business, with a marketing presence in 100+ countries.


OUR RECOMMENDATION:

MOMENTUM SWING: BUY SEQUENT BETWEEN 143-144 TARGETS 155-167 STOP LOSS BELOW 133

MARKET CAP	P/E	DIVIDEND YIELD	ROCE	ROE	FACE VALUE	3YEARS SALES GROWTH	3YEARS PROFIT GROWTH
RS.3,692 CR.	-	0 %	0.90 %	-2.46 %	2.00	0%	0%



SHAREHOLDING PATTERN MARCH 24



TECHNICAL ANALYSIS

The chart represents the 30-minute price movement of Sequent stock on the NSE. The chart features several technical indicators, including the 200-period EMA, 55-period EMA, 21-period EMA, and SuperTrend. The stock has shown a significant uptrend starting from late June, with a notable price jump around July 3. The price is currently above the 200-period EMA, suggesting a bullish long-term trend. The recent pullback to around 134 levels was met with support, and the stock has bounced back above the 55 and 21-period EMAs,

indicating renewed bullish momentum. The SuperTrend indicator turned positive, supporting the bullish outlook.

DISCLAIMER

I, **Ruchi Nahar**, SEBI Registered Research Analyst (**INH000014544**) comply with the qualification and certification requirements under SEBI (Research Analyst) Regulations, 2014. I have qualified **CA, CS and MBA**, has over 11 years of experience in MNCs, culminating as Head of Finance. I now leverage my expertise to guide stock market investors with strategic insights. All of the views expressed in research reports and recommendations issued by me reflect my personal views about the subject company or companies at the given point of time and I do not receive/accept any kind of compensation, directly or indirectly related to specific recommendations or views expressed in reports issued by me. I/my relatives do not at any point of time of issuing the reports have any material conflict of interest in the subject company neither I was/am/will be engaged in market making activity for the subject company. The investments discussed or views expressed in reports and recommendations issued by me may not be suitable for all investors. The user assumes the entire risk of any use made of this information. I nor any person connected with my report, accepts any liability arising from the use of research document. The recipients of research document should rely on their own investigations and should consult their own financial advisors to determine merit and risks of such investments based on their own risk appetite. Price and value of the investments referred to in this material may go up or down. Past performance is not a guide for future performance. Certain transactions including those involving futures, options and other derivatives as well as non-investment grade securities involve substantial risk and are not suitable for all investors. Reports and recommendations based on technical analysis centres on studying charts of a stock's price movement and trading volume, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals. Opinions expressed in research reports & recommendations will be based on the current opinions as of the date appearing in research report & recommendations. While I endeavour to update on a reasonable basis the information discussed in research reports, there may be regulatory, compliance, or other reasons that prevent me from doing so. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice. So far as reports include current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed. Investment in securities market is subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.